VC  Hunt BioVentures

http://www.huntbioventures.com





     Office Locations:

1900 North Akard Street
Dallas, TX 75201
Phone: 214-978-8690
Fax: 214-978-8180

 

Stages:

  • Early


 

Industries:

  • Food & Agriculture
  • Life Sciences & Healthcare

  •  

    Description:

    Hunt BioVentures makes investments in young private companies with a focus on pharmaceuticals, medical devices and agriculture biotech opportunities. Formed in 2001, Hunt has continually pursued companies with clinical efficacy data or strong human proxy data, which has typically meant companies with products in various stages of clinical trials. Although the firm usually targets later stage companies, Hunt will occasionally pursue pre-clinical opportunities, especially those with exceptional management teams. Another important component of the strategy is to invest alongside other experienced life science investors in either a 'co-lead' or 'follower' manner. Hunt invests $2 million to $5 million per round of a company's evolution with no ceiling on the total capital invested in any one company. Although Hunt operates much like a fund, it does not manage third party capital, but instead invests capital generated by other Hunt affiliates.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Mike Bierman Managing Director

     

    Portfolio companies include:


      Acorda
        web link


      Athenix
        web link


      Cempra Pharmaceuticals
        web link


      MacroGenics
        web link


      Morphotek


      Myogen
        web link


      OvaScience
        web link


      Revance Therapeutics
        web link


      Salmedix
        web link


      Sirtris
        web link


      Synageva
        web link


     

    Recent News: